Fosun Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Shanghai Fosun Pharmaceutical Group Co Ltd (600196)
The FOSUNPHARMA share price today is 24.02, view SS 600196 stock exchange data. Track the latest FOSUNPHARMA share price with real-time updates on 600196 stock performance including market cap, day range, 52-week range and dividend yield. Access 600196 charts, earnings dates and analyst estimates to support your investment decisions.
24.02
+0.63(+2.69%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
23.26
24.10
52 wk Range
20.85
30.09
600196 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
23.2624.10
52 wk Range
20.8530.09
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.62%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.62%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
600196 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
33.64
Upside
+40.05%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high P/E ratio relative to near-term earnings growth
Fosun Pharm receives Investment Bank Analyst Rating Update- Investing.com
Pro
Fosun Pharm receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Fosun Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Fosun Pharm receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Fosun Pharma receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
4 Buy
2 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 33.64
(+40.05% Upside)
Earnings
Latest Release
25-08-2026
EPS / Forecast
0.32 / 0.36
Revenue / Forecast
10.33B / 10.66B
Compare 600196 to Peers and Sector
Metrics to compare | 600196 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship600196PeersSector | |
|---|---|---|---|---|
P/E Ratio | 17.4x | 16.4x | −0.3x | |
PEG Ratio | 3.34 | 0.14 | 0.00 | |
Price/Book | 1.2x | 2.0x | 2.6x | |
Price / LTM Sales | 1.4x | 2.3x | 3.0x | |
Upside (Analyst Target) | 40.1% | 28.4% | 56.4% | |
Fair Value Upside | Unlock | 12.0% | 7.2% | Unlock |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, cardiovascular system, and APIs and intermediates. It also offers mRNA vaccines; medical aesthetic devices, such as medical aesthetic capital equipment, aesthetic dentistry, injectables, and personal care business units; mechanical ventilation devices under the Breas brand; and mobile pre-hospital care; professional in-hospital surgery and covers medical devices; and high-end surgical robots and medical consumables. In addition, the company provides diagnostics solutions comprising biochemical diagnostics, immune diagnostics, molecular diagnostics, microbiological diagnostics, pathological diagnostics, and chronic care management; and healthcare services, specialized medical treatment, online and offline medical services, and insurance services. Further, it engages in the operation of hospitals; and distribution and retail of healthcare products. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the FOSUNPHARMA (600196) Share Price Today?
The FOSUNPHARMA share price today is 24.02.
What is the current FOSUNPHARMA (600196) share price and day range?
As of 01-10-2026, the FOSUNPHARMA share price is 24.02, with a previous close of 24.02. The share price has ranged from 23.26 to 24.10 today, while the 52-week range spans from 20.85 to 30.09.
What Is the FOSUNPHARMA Market Cap?
As of today, FOSUNPHARMA market cap is 58.95B.
Does FOSUNPHARMA Pay Dividends? What's The Current Dividend Yield?
The FOSUNPHARMA dividend yield is 1.62%.
What Is the FOSUNPHARMA (600196) Share Price Target?
The average 12-month share price target for FOSUNPHARMA is 33.64, with a high estimate of 44 and a low estimate of 24.8. 4 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +40.05% Upside potential.
What Is FOSUNPHARMA's Earnings Per Share (TTM)?
The FOSUNPHARMA EPS (TTM) is 1.28.
When Is the Next FOSUNPHARMA Earnings Date?
FOSUNPHARMA will release its next earnings report on 28-10-2026.
From a Technical Analysis Perspective, Is 600196 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does FOSUNPHARMA Trade On?
FOSUNPHARMA is listed and trades on the Shanghai Stock Exchange.
What Is the Stock Symbol for FOSUNPHARMA?
The stock symbol for FOSUNPHARMA is "600196."
How Many Times Has FOSUNPHARMA Stock Split?
FOSUNPHARMA has split 7 times.
How Many Employees Does FOSUNPHARMA Have?
FOSUNPHARMA has 40684 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.